ReviewCurrent oncology (Toronto, Ont.)2020
Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
Review in Current oncology (Toronto, Ont.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Impact of dermatology targeted immunotherapies on autoimmune thyroid diseases: cytokine-network crosstalk and thyroid safety.Frontiers in immunology · 2026Review
- Immune checkpoint inhibitors and endocrinopathies in pediatric brain tumor patients.Journal of pediatric endocrinology & metabolism : JPEM · 2025Article
- A Real-World Comparison of the Safety Profile for Immune Checkpoint Inhibitors in Oncology Patients.Journal of clinical medicine · 2025Article
- Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1.EXCLI journal · 2024Review
- T-cell tolerant fraction as a predictor of immune-related adverse events.Journal for immunotherapy of cancer · 2023Article
- Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors.Frontiers in immunology · 2023Article
- Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma.Cancers · 2022Review
- Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab.Endocrine oncology (Bristol, England) · 2022Article
- Article
- Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma.Journal of clinical medicine · 2021Review
- [Side effects of immune checkpoint inhibitor treatment of urological tumors].Der Urologe. Ausg. A · 2021Article
- Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.Journal of cancer immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitor therapy (icit) is now a standard of care for a variety of cancers in both the metastatic and adjuvant settings. As a result, an understanding of the timing, epidemiology, monitoring, diagnosis, and management of immune-related adverse events (iraes) associated with icit is imperative. This article reviews specific iraes by organ system, consolidating recommendations from multiple guidelines and incorporating data from case reports to highlight additional evolving therapeutic options for patients. Managing iraes requires early recognition, early intervention, and education of the patients and the multidisciplinary health care team alike. Given the durable responses observed with icit, and the irreversible nature of some of the iraes, further research into management of the sequelae of icit is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.